/
Oncology
Recurrent Multiple Myeloma
20
Pipeline Programs↗
11
Active Trials↗
10
Companies Involved↗
Recurrent Multiple Myeloma is an emerging landscape with 20 programs across 10 companies. The most active players are GSK, Regeneron.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 19
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
19programs
Small molecule1158%
Monoclonal antibody526%
Protein / enzyme211%
Cell therapy15%
Modality classified for 95% of 20 pipeline programs.
Analysis
Trial Status
14
clinical trials
Recruiting8 · 57%
Active, not recruiting2 · 14%
Suspended1 · 7%
Not yet recruiting1 · 7%
Terminated1 · 7%
Completed1 · 7%
Clinical Trials
Trial Activity
14 trials
A Phase Ib Study of TGFbi NK Cells and Isatuximab for Myeloma Relapsed/Refractory to BCMA Targeting Therapy
Completed·—·Phase 1·NCT06203912·3 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)